Drug
intranasal Oxytocin(24IU)
intranasal Oxytocin(24IU) is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)
Highest Phase Reached
UnknownTrial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
N/A
Trials by Phase
N/A2 (100.0%)
Trials by Status
completed2100%
Recent Activity
Clinical Trials (2)
Showing 2 of 2 trials
NCT05892939Not Applicable
Effects of Intranasal Oxytocin on Fear Processing in Naturalistic Contexts
NCT05896553Not Applicable
Effects of Oxytocin on the Functional Architecture of the Brain Before and After Prolonged Naturalistic Fear Induction
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2